Drugmakers are reducing reliance on Chinese contractors for drug production, benefiting Indian rivals. Health insurers in the US are avoiding paying for expensive treatments, leading to increased industry profits. Moderna has started constructing a mRNA manufacturing site in China. State and local governments are suing insulin makers and pharmacy benefit managers over price conspiracy. A law protecting patients from surprise medical bills is causing financial strain on some healthcare providers, leading to bankruptcy filings.
A law designed to protect patients from surprise medical bills is denting the finances of some healthcare providers, with a few major ones filing for bankruptcy https://t.co/dXe21LO2eW
A growing number of state and local governments are suing insulin makers and pharmacy benefit managers over claims the companies conspired to illegally drive up prices. https://t.co/LW3I9PK1cb
U.S. vaccine maker Moderna began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday. https://t.co/62fNlV570R
Moderna begins work on China mRNA manufacturing site https://t.co/BxcCAP181Q https://t.co/TQpJ9lxSuu
Moderna begins work on China mRNA manufacturing site https://t.co/pSXqGeYtZH https://t.co/S071FXdSvH
Across the US, health insurers are flouting state laws created to guarantee access to critical medical care, like cancer treatments. And as the companies continue to dodge bills for pricey treatments, their industry profits have risen. w/ @scrippsnews https://t.co/dAiVxP421j
Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India https://t.co/ABGnZ0VMyO